/

Electronics & Software

/

Medios

Medios

Medios

Verified Nov 2026

Electronics & Software

·

Germany flag

Berlin, Berlin

·

Since 2015

Medios is a Berlin-based specialty pharmaceutical provider established in 2015, operating across Germany, the Netherlands, Belgium, and Spain with 500-1,000 employees and estimated revenue of €1.8 billion as of 2023. The company composes patient-specific medications, manufactures cytostatic drugs, and distributes high-priced specialty pharmaceuticals for oncology and neurology therapies. Medios acquired a 74% stake in Caelo in 2026 to strengthen its position in active pharmaceutical ingredients and excipients across Europe.

Medios

Verified Nov 2026

AT A GLANCE

Founded

2015

Headquarters

Germany flag

Berlin, Berlin

Employees

500-1,000

Ownership

Medios at a glance

Revenue

$1-5B

Est. band

Employees

500-1,000

Founded

2015

Headquarters

Berlin, Berlin

Import activity

65

Industries

Automotive

Electric Vehicles

Medical

Sourcing and import activity

From US customs bill-of-lading records

US sea imports

65

Named foreign suppliers

7

Top origins

Spain · Italy · Belgium

Chart of the supplier's US import shipment volume trend over time

Shared foreign counterparties do not establish that these companies buy from Medios.

What this tells a buyer

Medios receives shipments from suppliers across Spain, Italy, and Belgium, with over 1,700 recorded inbound shipments from sources including Sefar and Saati.

The company offers compounding of custom medications, cytostatic drug manufacturing, specialized antibody therapies, and wholesale distribution of high-priced specialty drugs, supported by Medios Digital software solutions for operational efficiency.

Medios set an ambition in 2026 to reach €3.1 billion in revenue and double adjusted EBITDA by 2031, reflecting expansion in its specialty pharma operations.

Source: US customs bill-of-lading records and public filings · Last verified Nov 13, 2026

STABILITY SIGNALS

Operating

11 years in operation (founded 2015).

65 US import shipments on record.

Overview

Medios is a Berlin-based specialty pharmaceutical provider established in 2015, operating across Germany, the Netherlands, Belgium, and Spain with 500-1,000 employees and estimated revenue of €1.8 billion as of 2023. The company composes patient-specific medications, manufactures cytostatic drugs, and distributes high-priced specialty pharmaceuticals for oncology and neurology therapies. Medios acquired a 74% stake in Caelo in 2026 to strengthen its position in active pharmaceutical ingredients and excipients across Europe.

At a glance

Attribute

Detail

Founded

2015

Headquarters

Berlin, Berlin

Employees

500-1,000

Revenue

$1-5B (estimated)

Primary capability

Electronics & Software

What Medios makes

The company offers compounding of custom medications, cytostatic drug manufacturing, specialized antibody therapies, and wholesale distribution of high-priced specialty drugs, supported by Medios Digital software solutions for operational efficiency.

Trade and customs footprint

Medios receives shipments from suppliers across Spain, Italy, and Belgium, with over 1,700 recorded inbound shipments from sources including Sefar and Saati. US customs bill-of-lading records list 65 inbound shipments across 7 foreign suppliers, with top origins including Spain · Italy · Belgium.

Latest developments

Company details

Medios set an ambition in 2026 to reach €3.1 billion in revenue and double adjusted EBITDA by 2031, reflecting expansion in its specialty pharma operations. Medios was founded in 2015, has an estimated 500-1,000 employees, and is headquartered in Berlin, Berlin. On the LightSource stability read it is rated "Operating": 11 years in operation (founded 2015). 65 US import shipments on record.

Frequently asked questions

What does Medios make?

Medios is a Berlin-based specialty pharmaceutical provider established in 2015, operating across Germany, the Netherlands, Belgium, and Spain with 500-1,000 employees and estimated revenue of €1.8 billion as of 2023. The company composes patient-specific medications, manufactures cytostatic drugs, and distributes high-priced specialty pharmaceuticals for oncology and neurology therapies. Medios acquired a 74% stake in Caelo in 2026 to strengthen its position in active pharmaceutical ingredients and excipients across Europe.

Where is Medios headquartered?

Medios is headquartered in Berlin, Berlin.

When was Medios founded?

Medios was founded in 2015.

How big is Medios?

Medios has an estimated 500-1,000 employees, with revenue in the $1-5B range (estimated).

Does Medios import from overseas suppliers?

US customs bill-of-lading records show 65 inbound shipments for Medios, with top origins including Spain · Italy · Belgium.

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

Berlin, Berlin (HQ)Headquarters · Berlin, Germany
Berlin, Berlin (HQ)Berlin, Berlin, GermanyHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.